Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
August 23, 2021- NRx Pharmaceuticals to lead BriLife Vaccine Trial in Caucasus RegionNRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports1 in the Israeli media that participants in the BriLife vaccine trial who received the...
-
August 16, 2021- Emergency Use Authorization (EUA) Request for ZYESAMI™ (aviptadil) Pending with United States Food and Drug Administration to Treat Patients Suffering from Critical COVID-19 with Respiratory Failure
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a...
-
August 11, 2021--Company to Host Conference Call August 17, 2021 at 8:30AM ET--
RADNOR, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company, today announced that management will report second...
-
August 10, 2021NRx Advancing Investigational Medicines for Critical COVID-19 and Other Respiratory Conditions, Vaccine to Prevent COVID-19 and Breakthrough Drug for Suicidal Depression and PTSD
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with Prof Jonathan Javitt, Founder, Chairman and CEO of...
-
August 9, 2021-Dose-Confirmatory Trial Follows Successful Phase 2a Trial
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the BriLife™ vaccine against...
Click here to view our corporate presentation or on the image below
 |
